Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sphinx university | OTHER |
Not provided
Not provided
Not provided
Not provided
evaluate clinically and biochemically the efficacy of topically applied selenium as complementary or alternative to triamcinolone acetonide 0.1% and tacrolimus 0.1% in patients with oral lichen planus.
The signs and symptoms of the oral lichen planus lesion. 2-The associated oral symptoms. 3- Glutathione biomarker level as an antioxidant enzyme in saliva by ELISA analysis .
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| group I (triamcinolone) | Placebo Comparator | ten patients with oral lichen planus, will receive topical triamcinolone acetonide 0.1% four times per day for six weeks. |
|
| group II (tacrollimus) | Placebo Comparator | ten patients with oral lichen planus, will receive topical tacrolimus 0.1% four times per day for six weeks. |
|
| group III (selenium) | Experimental | ten patients with oral lichen planus, will receive topical selenium four times per day for six weeks. |
|
| group IV (selenium + triamcinolone ) | Experimental | : ten patients with oral lichen planus, will receive topical selenium combined with topical triamcinolone acetonide 0.1% three times per day for each for six weeks |
|
| group V ( selenium + tacrollimus) | Experimental | ten patients with oral lichen planus, will receive topical selenium combined with topical tacrolimus 0.1% three times per day for each for six weeks. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Triamcinolone Acetonide 0.1% Oint | Drug | RCT |
|
| Measure | Description | Time Frame |
|---|---|---|
| to assess a visual analog scale (VAS)of the oral lichen planus lesion | qualitative | baseline, 1, 3 and 6 months after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| to assess The associated Oral Disease Severity Score 3- Glutathione biomarker level as an antioxidant enzyme in saliva by ELISA analysis | qualitative ,and quantitiave | baseline, 1, 3 and 6 months after treatment |
| Biochemical evaluation of salivary Glutathione level using (ELISA) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alazhar university ,faculty of Dental Medicine | Asyut | 0000 | Egypt |
Not provided
| Label | URL |
|---|---|
| orcid | View source |
| ncbi | View source |
Not provided
All patients were recruited from the outpatient clinic of the Dermatology Department, Assiut University Hospitals, and referred to oral Medicine clinics, Faculty of Dental Medicine, Al-Azhar University, Assiut branch.
ready now
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Dec 30, 2025 | |
| Unrelease | Jan 3, 2026 | |
| Release | Jan 6, 2026 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Tacrollimus Topical | Drug | RCT |
|
|
| Selenium | Drug | RCT |
|
|
| Selenium & Triamcinolone Acetonide 0.1% Oint | Drug | RCT |
|
|
| Selenium& Tacrollimus topical | Drug | RCT |
|
|
Quantity |
| baseline, 1, 3 months after treatment |
| Unrelease | Jan 16, 2026 |
| Release | Jan 16, 2026 |
| Reset | Feb 2, 2026 |
| Release | Feb 2, 2026 |
| Unrelease | Feb 9, 2026 |
| Release | Mar 7, 2026 |
| Reset | Mar 26, 2026 |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Dec 30, 2025 | Jan 3, 2026 | |||
| Jan 6, 2026 | Jan 16, 2026 | |||
| Jan 16, 2026 | Feb 2, 2026 | |||
| Feb 2, 2026 | Feb 9, 2026 | |||
| Mar 7, 2026 | Mar 26, 2026 |
| ID | Term |
|---|---|
| D017676 | Lichen Planus, Oral |
| ID | Term |
|---|---|
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D008010 | Lichen Planus |
| D017512 | Lichenoid Eruptions |
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014222 | Triamcinolone Acetonide |
| D009824 | Ointments |
| D012643 | Selenium |
| ID | Term |
|---|---|
| D014221 | Triamcinolone |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |
| D018011 | Chalcogens |
| D004602 | Elements |
| D007287 | Inorganic Chemicals |
| D008903 | Minerals |
Not provided
Not provided